Dr. Mitchell D. Efros, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- New York Medical College (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,023
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: New York Medical College
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
NY license 173384
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 1,023
- Services billed
- 11,856
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Automated urinalysis test | 1,751 | 960 |
| Ultrasound measurement of bladder capacity after voiding | 1,425 | 811 |
| Bacterial colony count, urine | 1,308 | 726 |
| Established patient office or other outpatient visit, 30-39 minutes | 946 | 593 |
| Established patient office or other outpatient visit, 20-29 minutes | 807 | 578 |
| Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral), microdilution or agar dilution | 417 | 164 |
| Bacterial culture for aerobic isolates | 265 | 175 |
| Bacterial urine culture | 265 | 175 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 163 | 159 |
| Electronic assessment of bladder emptying | 158 | 154 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Garden City, NY | 342 |
| Finasteride Other prescribers in Garden City, NY | 173 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Garden City, NY | 84 |
| Myrbetriq (mirabegron) Other prescribers in Garden City, NY | 84 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Garden City, NY | 81 |
| Dutasteride Other prescribers in Garden City, NY | 54 |
| Cephalexin Other prescribers in Garden City, NY | 52 |
| Cefdinir Other prescribers in Garden City, NY | 50 |
| Sildenafil Citrate Other prescribers in Garden City, NY | 47 |
| Gemtesa (vibegron) Other prescribers in Garden City, NY | 45 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 29 payments worth $794 in total to this clinician.
| AbbVie Inc. | $228 |
|---|---|
| Sumitomo Pharma America, Inc. | $170 |
| Procept Biorobotics Corporation | $108 |
| Urogen Pharma, Inc. | $94.92 |
| Teleflex LLC | $54.06 |
| Tolmar, Inc. | $29.25 |
| Progenics Pharmaceuticals, Inc. | $28.80 |
| Pfizer Inc. | $25.07 |
| Food and Beverage | $794 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 6 companies. The companies reported $193,228 in research payments for these studies, mostly to the institutions running them.
- TOL-CLAR-20024
Tolmar, Inc. - Study name not reported
Ironwood Pharmaceuticals, Inc - A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Global Development - Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06510374 - A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction …
Ibsa Institut Biochimique SA - PINNACLE
Laborie Medical Technologies Corp.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.